WO2012067398A2 - Composition for whitening skin containing phlomis koraiensis nakai extract as active ingredient - Google Patents

Composition for whitening skin containing phlomis koraiensis nakai extract as active ingredient Download PDF

Info

Publication number
WO2012067398A2
WO2012067398A2 PCT/KR2011/008693 KR2011008693W WO2012067398A2 WO 2012067398 A2 WO2012067398 A2 WO 2012067398A2 KR 2011008693 W KR2011008693 W KR 2011008693W WO 2012067398 A2 WO2012067398 A2 WO 2012067398A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
extract
acid
skin
skin whitening
Prior art date
Application number
PCT/KR2011/008693
Other languages
French (fr)
Korean (ko)
Other versions
WO2012067398A3 (en
Inventor
이옥찬
노호식
황경환
조가영
김덕희
김한곤
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2012067398A2 publication Critical patent/WO2012067398A2/en
Publication of WO2012067398A3 publication Critical patent/WO2012067398A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • the present invention relates to a composition for skin whitening containing acid extract as an active ingredient.
  • Human skin color is determined by a number of factors, including the activity of melanocytes that make melanin pigment, the distribution of blood vessels, the thickness of the skin, and the presence or absence of pigments in and outside the body, such as carotenoids and bilirubin.
  • the most important is the black pigment called melanin produced by the action of various enzymes such as.
  • the formation of melanin pigment is influenced by genetic factors, physiological factors related to hormone secretion, stress, and environmental factors such as ultraviolet irradiation. Melanin is present in the skin and has an important function of protecting the body from ultraviolet rays, but when it is overproduced, melanin is known to not only form spots and freckles, but also promote skin aging and cause skin cancer.
  • the same tyrosinase-inhibiting substances have been used in cosmetics and pharmaceuticals, but they are limited in use due to insufficient whitening effects, safety issues on the skin, formulation in cosmetics, and stability in formulations. It is true.
  • An object of the present invention is to provide a composition for skin whitening having a safe skin and excellent whitening effect by containing an acid-based extract, which is a vegetable natural raw material, as an active ingredient.
  • the present invention provides a composition for skin whitening containing acid extract as an active ingredient.
  • the acid fast extract is a group consisting of anhydrous and hydrous lower alcohol having 1 to 4 carbon atoms, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane It may be extracted using one or more solvents selected from.
  • the acid-fast extract, primary extraction and ethyl acetate, diacetic acid using any one or more of a polar solvent containing anhydrous and hydrous lower alcohol, acetone and butylene glycol having 1 to 4 carbon atoms It may be extracted through secondary extraction using any one or more of a low polar solvent including ethyl acetate, diethyl ether, benzene, chloroform and hexane.
  • the content of the acid flux may be 0.0001 to 10% by weight based on the total weight of the composition.
  • the skin whitening composition may be to whiten the skin through the inhibition of melanin production.
  • the skin whitening composition may be to whiten the skin through inhibiting tyrosinase activity.
  • composition for skin whitening containing the acid extract of the present invention as an active ingredient has safety for the skin and is excellent in inhibiting tyrosinase activity and inhibiting melanin production, and thus may be usefully applied to external skin preparations for the purpose of whitening.
  • the present invention provides a composition for skin whitening containing an acid extract as an active ingredient.
  • the mountain genus is a perennial herb of Lamiaceae, and its scientific name is Phlomis Korainensis Nakai.
  • the mountain range grows in the deep mountains. The leaves are facing each other and have a stand about 60cm in height. The flowers bloom in August ⁇ September, turn red, and run in layers at the end of the far end. The roots are fusiform, enlarged and spread in all directions.
  • the mountain range is a special species of Korea, and is distributed in Hamgyongnamdo, North Hamgyongbukdo, Pyongannamdo, and Pyonganbukdo. In the private sector, the roots of mountainous peaks were called tosokdan ( ⁇ ⁇ ⁇ ) and used for bruises and gynecological diseases. However, there have been no studies on the inhibition and whitening efficacy of tyrosinase activity of acid groups.
  • Acid flux extract of the present invention is dried and pulverized root of the acid flux;
  • the pulverized product obtained above is any one or more extraction solvents selected from the group consisting of anhydrous and hydrous lower alcohols having 1 to 4 carbon atoms, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane. Extraction is performed one or more times by cooling or warming;
  • the extract obtained above may be prepared by concentrating under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser.
  • the extraction step is more preferably, after the primary extraction using any one or more of a polar solvent containing anhydrous and hydrous lower alcohol having 1 to 4 carbon atoms, acetone and butylene glycol, and then sequentially ethyl acetate, diethyl
  • the extraction may be performed through secondary extraction using any one or more of a low polar solvent including acetate, diethyl ether, benzene, chloroform and hexane.
  • an extraction solvent water, anhydrous and hydrous lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, normal propanol, normal butanol), a mixture of water and lower alcohols, acetone, 1,3-butylene glycol, isopropanol
  • the polar solvent and the mixed solvent thereof are added by 5 to 20 times by volume to the dry weight of the pulverized product of the root of the acid stream, and the resulting mixture is extracted by filtration and concentrated under reduced pressure.
  • Extraction method is carried out for about 12 to 96 hours in the case of cold needle, or aged for 4 to 20 days at room temperature of 4 to 25 °C using an anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, ethyl acetate or diethyl ether as a solvent to extract the active ingredient.
  • anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, ethyl acetate or diethyl ether as a solvent
  • it is different depending on the type and temperature of the extraction solvent, but it is preferably carried out at a temperature close to the reflux temperature of the solvent for about 5 to 24 hours.
  • the acid flux extract is preferably contained from 0.0001 to 10% by weight based on the total weight of the composition.
  • the acid flux extract is included in less than 0.0001% by weight relative to the total weight, the whitening effect is insignificant, and if it is more than 10% by weight, there is no apparent increase in effect with increasing content.
  • composition for skin whitening according to the present invention may be, for example, a pharmaceutical composition or a cosmetic composition.
  • the pharmaceutical composition for skin whitening may further contain pharmaceutical supplements such as preservatives, stabilizers, hydrating or emulsifiers, salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances. Accordingly, it can be formulated into various parenteral dosage forms.
  • Parenteral dosage forms may be transdermal dosage forms, for example, but not limited to, lotion, ointment, gel, cream, patch or spray formulations.
  • the dosage of the active ingredient is within the level of those skilled in the art, and the daily dosage of the drug depends on various factors such as less progression, onset, age, health condition, complications, etc. of the subject to be administered.
  • the composition may be administered by dividing 1 ⁇ g / kg to 200 mg / kg, preferably 50 ⁇ g / kg to 50 mg / kg, once or three times a day, and the dosage may be determined by any method. Nor does it limit the scope of the invention.
  • the cosmetic composition for skin whitening is not particularly limited in formulation, and may be appropriately selected as desired.
  • skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing It may be prepared in any one or more formulations selected from the group consisting of foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
  • the formulation of the present invention is a paste, cream or gel
  • animal carriers vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc.
  • carrier components can be used as carrier components.
  • lactose When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
  • a solvent, solvating or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
  • liquid carrier diluents such as water, ethanol or propylene glycol
  • suspension agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide.
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • the content of the active ingredient is not particularly limited, but may be included as 0.0001 to 10% by weight based on the total weight of the composition. When the active ingredient satisfies the content, it may exhibit excellent efficacy without side effects.
  • the cosmetic composition may further include functional additives and components included in the general cosmetic composition in addition to the acid flux extract prepared above.
  • the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
  • the present invention relates to an external preparation for skin comprising the composition for skin whitening
  • the external preparation for skin is a generic term that may include anything applied outside of the skin, and cosmetics and medicines of various formulations may be included therein.
  • the external preparation for the skin is also not particularly limited, but may be, for example, an external preparation for preventing skin aging or improving skin wrinkles.
  • the present invention has found an excellent skin whitening effect using a composition containing an acid extract, which is a natural raw material.
  • the composition for skin whitening according to the present invention can enhance skin whitening by having a function of inhibiting tyrosinase activity and inhibiting melanin production, as can be seen in the test examples described later.
  • the roots of the acid groups were washed with purified water, dried and then semalized.
  • 200 g of the granulated acidified root powder was placed in 1 liter of an aqueous 70% ethanol solution, extracted by boiling in an extractor equipped with a cooling condenser for 12 hours, and filtered through a 300 mesh filter cloth.
  • the filtrate was left to mature at 4-15 ° C. for 7 days and then filtered through Whatman No. 2 filter paper. Thereafter, the extract was added to a 3-liter separatory funnel, and 1 liter of ethyl acetate was added thereto, shaken well, the mixture was thoroughly separated, and the upper layer (ethyl acetate layer) was taken.
  • the lower layer (water layer) was again extracted twice with a separatory funnel.
  • the combined upper layers were combined, concentrated under reduced pressure at 50 ° C. using a distillation apparatus equipped with a cooling condenser, and dried to obtain an acidic extract having a dry weight of 25.5 g.
  • the tyrosinase activity inhibitory effect measurement test of the acid step extract of Example 1 was carried out. Tyrosinase activity was measured by Pomerantz and Oikawa et al. First, Mel-ab cells 2 ⁇ 10 4 cells were placed in a 6-well culture dish, and treated with 10, 50, and 100 ppm of the acid flux extract obtained in Example 1, and cultured for 24 hours. In addition, as a comparative example, 300 ppm of koji acid conventionally known as a whitening agent component was cultured by the same method. After 24 hours, 2 Ci [ 3 H] tyrosine / ml of [ 3 H] L-tyrosine was treated and incubated for another 24 hours. Thereafter, a cell culture was obtained to quantify the amount of 3 H 2 O, and the results are shown in Table 1 below.
  • the acid flux extract has a lower tyrosinase activity than the comparative example, and as the concentration of the acid flux extract increases, the tyrosinase activity decreases, and the acid flux extract has an inhibitory effect on tyrosinase activity. I could confirm it.
  • Example 1 Melanin production inhibitory effect measurement test of the acid step extract of Example 1 was carried out.
  • the degree of melanin production in the acid-producing extract of Example 1 was measured by Dooley's method.
  • kojic acid conventionally known as a whitening agent component was measured.
  • the cell line was a Mel-Ab cell line derived from C57BL / 6 skin pigment cells. The culture was performed at 37 ° C., 5% CO 2 in DMEM medium containing 10% fetal placental serum, 100 nM 12-O-tetradecanoyl Phobol-13-acetate, 1 nM Cholera Toxin. Under conditions.
  • the production amount of melanin of the acid-fast extract was reduced compared to the comparative example, and thus it was found that the acid-fast extract has an effect of inhibiting melanin production.
  • composition of this invention is not limited only to this example.
  • Xanthan gum (2% aqueous solution) 2.00

Abstract

A composition for whitening the skin containing Phlomis koreaiensis Nakai extract as an active ingredient of the present invention is safe for the skin, and can be usefully applied to a skin preparation for external use for whitening, due to superior tyrosinase activity and melanin generation inhibiting effects.

Description

산속단 추출물을 유효성분으로 함유하는 피부 미백용 조성물Skin whitening composition containing acidic extract as an active ingredient
본 발명은 산속단 추출물을 유효성분으로 함유하는 피부 미백용 조성물에 관한 것이다. The present invention relates to a composition for skin whitening containing acid extract as an active ingredient.
사람의 피부색은 멜라닌 색소를 만드는 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께 및, 카로티노이드 및 빌리루빈 등 인체 내외의 색소 함유 유무와 같은 여러 요인들에 의해 결정되며 그 중 멜라노사이트에서 티로시나제 등의 여러 효소가 작용하여 생성되는 멜라닌이라는 흑색 색소가 가장 중요하다. 멜라닌 색소의 형성에는 유전적 요인, 호르몬 분비, 스트레스 등과 관련된 생리적 요인 및 자외선 조사 등과 같은 환경적 요인이 영향을 미친다. 멜라닌은 피부에 존재하면서 자외선 등으로부터 신체를 보호하는 중요한 기능을 가지고 있지만, 멜라닌이 과잉 생산되는 경우에는 기미, 주근깨 등을 형성할 뿐 아니라 피부 노화를 촉진하고 피부암 유발에도 중요한 작용을 하는 것으로 알려져 있다 Human skin color is determined by a number of factors, including the activity of melanocytes that make melanin pigment, the distribution of blood vessels, the thickness of the skin, and the presence or absence of pigments in and outside the body, such as carotenoids and bilirubin. The most important is the black pigment called melanin produced by the action of various enzymes such as. The formation of melanin pigment is influenced by genetic factors, physiological factors related to hormone secretion, stress, and environmental factors such as ultraviolet irradiation. Melanin is present in the skin and has an important function of protecting the body from ultraviolet rays, but when it is overproduced, melanin is known to not only form spots and freckles, but also promote skin aging and cause skin cancer.
기미, 주근깨, 색소 침착 등과 같은 피부색소 이상 침착 증상과 자외선 노출 등에 의해 발생된 과도한 멜라닌 색소 침착을 치료 또는 경감시켜주기 위해서 이전부터 아스코르브산, 코지산, 알부틴, 하이드로퀴논, 글루타치온 또는 이들의 유도체와 같은 티로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합하여 사용하여 왔으나, 이들은 불충분한 미백효과, 피부에 대한 안전성 문제, 화장료에 배합시 제형화 및 제형 내 안정성 문제 등으로 인해 그 사용이 제한되고 있는 실정이다.Ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione or derivatives thereof in order to treat or alleviate the symptoms of abnormal skin pigmentation such as blemishes, freckles and pigmentation, and excessive melanin pigmentation caused by UV exposure. The same tyrosinase-inhibiting substances have been used in cosmetics and pharmaceuticals, but they are limited in use due to insufficient whitening effects, safety issues on the skin, formulation in cosmetics, and stability in formulations. It is true.
본 발명은 식물성 천연 원료인 산속단 추출물을 유효성분으로 함유함으로써, 피부에 대한 안전성을 가지며 미백 효과가 우수한 피부 미백용 조성물을 제공하는 것을 그 목적으로 한다.An object of the present invention is to provide a composition for skin whitening having a safe skin and excellent whitening effect by containing an acid-based extract, which is a vegetable natural raw material, as an active ingredient.
상기와 같은 목적을 해결하기 위하여 본 발명은 산속단 추출물을 유효성분으로 함유하는 피부 미백용 조성물을 제공한다. In order to solve the above object, the present invention provides a composition for skin whitening containing acid extract as an active ingredient.
본 발명의 일실시예에 있어서, 상기 산속단 추출물은 탄소수 1 내지 4의 무수 및 함수 저급 알코올, 아세톤, 부틸렌글리콜, 에틸아세테이트, 디에틸아세테이트, 디에틸에테르, 벤젠, 클로로포름 및 헥산으로 이루어진 군에서 선택된 어느 하나 이상의 용매를 사용하여 추출된 것일 수 있다.In one embodiment of the present invention, the acid fast extract is a group consisting of anhydrous and hydrous lower alcohol having 1 to 4 carbon atoms, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane It may be extracted using one or more solvents selected from.
본 발명의 일실시예에 있어서, 상기 산속단 추출물은, 탄소수 1 내지 4의 무수 및 함수 저급 알코올, 아세톤 및 부틸렌글리콜을 포함하는 극성 용매 중 어느 하나 이상을 사용한 1차 추출 및 에틸아세테이트, 디에틸아세테이트, 디에틸에테르, 벤젠, 클로로포름 및 헥산을 포함하는 저극성 용매 중 어느 하나 이상을 사용한 2차 추출을 통하여 추출된 것일 수 있다. In one embodiment of the present invention, the acid-fast extract, primary extraction and ethyl acetate, diacetic acid using any one or more of a polar solvent containing anhydrous and hydrous lower alcohol, acetone and butylene glycol having 1 to 4 carbon atoms It may be extracted through secondary extraction using any one or more of a low polar solvent including ethyl acetate, diethyl ether, benzene, chloroform and hexane.
본 발명의 일실시예에 있어서, 상기 산속단 추출물의 함량은 조성물 총 중량에 대하여 0.0001 내지 10중량%일 수 있다. In one embodiment of the present invention, the content of the acid flux may be 0.0001 to 10% by weight based on the total weight of the composition.
본 발명의 일실시예에 있어서, 상기 피부 미백용 조성물은 멜라닌 생성 억제를 통해 피부를 미백시키는 것일 수 있다. In one embodiment of the present invention, the skin whitening composition may be to whiten the skin through the inhibition of melanin production.
본 발명의 일실시예에 있어서, 상기 피부 미백용 조성물은 티로시나제 활성 억제를 통해 피부를 미백시키는 것일 수 있다. In one embodiment of the present invention, the skin whitening composition may be to whiten the skin through inhibiting tyrosinase activity.
본 발명의 산속단 추출물을 유효성분으로 함유하는 피부 미백용 조성물은 피부에 대한 안전성을 가지며 티로시나제 활성 억제 및 멜라닌 생성 억제 효과가 우수하여 미백을 목적으로 하는 피부 외용제에 유용하게 적용될 수 있다. The composition for skin whitening containing the acid extract of the present invention as an active ingredient has safety for the skin and is excellent in inhibiting tyrosinase activity and inhibiting melanin production, and thus may be usefully applied to external skin preparations for the purpose of whitening.
이하에서는, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 본 발명을 용이하게 실시할 수 있도록 하기 위하여, 본 발명의 바람직한 실시예들에 관하여 상세히 설명하기로 한다.Hereinafter, in order to enable those skilled in the art to easily carry out the present invention will be described in detail with respect to preferred embodiments of the present invention.
본 발명은 산속단 추출물을 유효성분으로 함유하는 피부 미백용 조성물을 제공한다. The present invention provides a composition for skin whitening containing an acid extract as an active ingredient.
산속단(山續斷)은 꿀풀과의 여러해살이풀로, 학명으로는 Phlomis Korainensis Nakai 등이 알려져 있다. 산속단은 깊은 산에서 자라며 높이는 60㎝ 정도로 잎은 마주 달리고 대가 있으며, 꽃은 8~9월에 피고 붉은빛이 돌며 원대 끝에 층층으로 달린다. 뿌리는 방추형으로 비대해져 사방으로 퍼진다. 산속단은 한국 특산종으로 함경남도·함경북도·평안남도·평안북도에 분포한다. 민간에서는 산속단의 뿌리를 토속단(土續斷)이라 하여 타박상 및 부인병 등에 사용하기도 하였다. 그러나 현재까지 산속단의 티로시나제 활성 억제 및 미백 효능에 대해서는 연구된 바가 없었다.The mountain genus is a perennial herb of Lamiaceae, and its scientific name is Phlomis Korainensis Nakai. The mountain range grows in the deep mountains. The leaves are facing each other and have a stand about 60cm in height. The flowers bloom in August ~ September, turn red, and run in layers at the end of the far end. The roots are fusiform, enlarged and spread in all directions. The mountain range is a special species of Korea, and is distributed in Hamgyongnamdo, North Hamgyongbukdo, Pyongannamdo, and Pyonganbukdo. In the private sector, the roots of mountainous peaks were called tosokdan (土 續 斷) and used for bruises and gynecological diseases. However, there have been no studies on the inhibition and whitening efficacy of tyrosinase activity of acid groups.
본 발명에서는 산속단의 뿌리를 사용하는 것이 바람직하다. 본 발명의 산속단 추출물은 산속단의 뿌리를 건조 및 분쇄하고; 상기에서 얻어진 분쇄물을 탄소수 1 내지 4의 무수 및 함수 저급 알코올, 아세톤, 부틸렌글리콜, 에틸아세테이트, 디에틸아세테이트, 디에틸에테르, 벤젠, 클로로포름 및 헥산으로 이루어진 군에서 선택된 어느 하나 이상의 추출용매로 냉침 또는 온침하여 1회 이상 추출하고; 상기에서 얻어진 추출물을 냉각 콘덴서가 달린 증류 장치에서 적정 온도로 감압 농축;하여 제조될 수 있다. In the present invention, it is preferable to use the root of the acid group. Acid flux extract of the present invention is dried and pulverized root of the acid flux; The pulverized product obtained above is any one or more extraction solvents selected from the group consisting of anhydrous and hydrous lower alcohols having 1 to 4 carbon atoms, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane. Extraction is performed one or more times by cooling or warming; The extract obtained above may be prepared by concentrating under reduced pressure to an appropriate temperature in a distillation apparatus equipped with a cooling condenser.
상기 추출 단계는 더욱 바람직하게는, 탄소수 1 내지 4의 무수 및 함수 저급 알코올, 아세톤 및 부틸렌글리콜을 포함하는 극성 용매 중 어느 하나 이상을 사용한 1차 추출을 한 후, 순차적으로 에틸아세테이트, 디에틸아세테이트, 디에틸에테르, 벤젠, 클로로포름 및 헥산을 포함하는 저극성 용매 중 어느 하나 이상을 사용한 2차 추출을 통하여 추출하는 것일 수 있다. 더욱 구체적으로, 추출용매로서 물, 탄소수 1 내지 4의 무수 및 함수 저급 알코올(메탄올, 에탄올, 노말 프로판올, 노말 부탄올), 물과 저급 알코올의 혼합물, 아세톤, 1,3-부틸렌글리콜, 이소프로판올을 포함하는 극성 용매와 이들의 혼합 용매를, 산속단의 뿌리의 분쇄물 건조 중량에 대하여 5 내지 20배 부피량을 가하여 침적 추출하여 여과한 후 여액을 감압 농축한다. 얻어진 농축액에 물을 가하여 분산시킨 후 분산액에 동량의 에틸아세테이트, 디에틸아세테이트, 디에틸에테르, 벤젠, 클로로포름 및 헥산을 포함하는 저극성 유기 용매를 가하고 진탕한다. 그 후 유기층을 분리한 후 감압농축하여 산속단 추출물을 얻는다. The extraction step is more preferably, after the primary extraction using any one or more of a polar solvent containing anhydrous and hydrous lower alcohol having 1 to 4 carbon atoms, acetone and butylene glycol, and then sequentially ethyl acetate, diethyl The extraction may be performed through secondary extraction using any one or more of a low polar solvent including acetate, diethyl ether, benzene, chloroform and hexane. More specifically, as an extraction solvent, water, anhydrous and hydrous lower alcohols having 1 to 4 carbon atoms (methanol, ethanol, normal propanol, normal butanol), a mixture of water and lower alcohols, acetone, 1,3-butylene glycol, isopropanol The polar solvent and the mixed solvent thereof are added by 5 to 20 times by volume to the dry weight of the pulverized product of the root of the acid stream, and the resulting mixture is extracted by filtration and concentrated under reduced pressure. Water is added to the resulting concentrate to disperse the mixture, followed by shaking with a low polar organic solvent containing the same amount of ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane. Thereafter, the organic layer is separated and concentrated under reduced pressure to obtain an acid step extract.
추출 방법으로는 냉침의 경우 약 12 내지 96시간동안 행하거나, 탄소수 1 내지 4개의 무수 또는 함수 저급 알코올, 에틸아세테이트 또는 디에틸에테르 등을 용매로 하여 4 내지 25℃ 상온에서 3 내지 20일 방치 숙성시켜서 유효성분을 추출할 수 있다. 온침의 경우는 추출용매의 종류와 온도에 따라 상이하나, 용매의 환류 온도에 가까운 온도로 약 5 내지 24시간동안 행하는 것이 바람직하다.Extraction method is carried out for about 12 to 96 hours in the case of cold needle, or aged for 4 to 20 days at room temperature of 4 to 25 ℃ using an anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, ethyl acetate or diethyl ether as a solvent To extract the active ingredient. In the case of warm needle, it is different depending on the type and temperature of the extraction solvent, but it is preferably carried out at a temperature close to the reflux temperature of the solvent for about 5 to 24 hours.
상기와 같은 극성 변화에 따라 순차적으로 추출하는 추출방법에 의하여, 활성성분의 함량을 극대화시키고 불순물을 제거하여 안정도가 향상됨과 동시에 효능이 극대화된 추출물을 얻을 수 있다. By the extraction method to extract sequentially according to the polarity change as described above, it is possible to obtain the extract to maximize the content of the active ingredient and remove impurities to improve stability and at the same time maximize the efficacy.
상기 산속단 추출물은 조성물 총 중량에 대하여 0.0001 내지 10중량% 포함되는 것이 바람직하다. 산속단 추출물이 총 중량에 비해 0.0001중량% 미만으로 포함되면 미백 효과가 미미하고, 10중량% 초과이면 함유량 증가에 따른 뚜렷한 효과의 증가가 나타나지 않는다. The acid flux extract is preferably contained from 0.0001 to 10% by weight based on the total weight of the composition. When the acid flux extract is included in less than 0.0001% by weight relative to the total weight, the whitening effect is insignificant, and if it is more than 10% by weight, there is no apparent increase in effect with increasing content.
본 발명에 따른 피부 미백용 조성물은 예를 들어, 약학 조성물 또는 화장료 조성물일 수 있다.The composition for skin whitening according to the present invention may be, for example, a pharmaceutical composition or a cosmetic composition.
상기 피부 미백용 약학 조성물에는 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 비경구 투여 형태로 제형화할 수 있다. 비경구 투여 형태로 경피 투여형 제형일 수 있으며, 예를 들어 로션, 연고, 겔, 크림, 패취 또는 분무제 제형일 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition for skin whitening may further contain pharmaceutical supplements such as preservatives, stabilizers, hydrating or emulsifiers, salts and / or buffers for the control of osmotic pressure, and other therapeutically useful substances. Accordingly, it can be formulated into various parenteral dosage forms. Parenteral dosage forms may be transdermal dosage forms, for example, but not limited to, lotion, ointment, gel, cream, patch or spray formulations.
상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 약물의 1일 투여 용량은 투여하고자 하는 대상의 미만 진행 정도, 발병 시기, 연령, 건강상태, 합병증 등의 다양한 요인에 따라 달라지지만, 성인을 기준으로 할 때 일반적으로는 상기 조성물 1㎍/kg 내지 200mg/kg, 바람직하게는 50㎍/kg 내지 50mg/kg을 1일 1 내지 3회 분할하여 투여할 수 있으며, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.Determination of the dosage of the active ingredient is within the level of those skilled in the art, and the daily dosage of the drug depends on various factors such as less progression, onset, age, health condition, complications, etc. of the subject to be administered. Generally, the composition may be administered by dividing 1 μg / kg to 200 mg / kg, preferably 50 μg / kg to 50 mg / kg, once or three times a day, and the dosage may be determined by any method. Nor does it limit the scope of the invention.
상기 피부 미백용 화장료 조성물은 제형이 특별히 한정되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 이루어진 군으로부터 선택된 어느 하나 이상의 제형으로 제조될 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition for skin whitening is not particularly limited in formulation, and may be appropriately selected as desired. For example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing It may be prepared in any one or more formulations selected from the group consisting of foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal carriers, vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc. may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspension agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, the carrier component is aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
상기 유효 성분의 함량은 특별히 제한되지 않으나, 조성물 총 중량을 기준으로 0.0001 내지 10 중량%로 포함될 수 있다. 상기 유효 성분이 상기 함량을 만족하는 경우 부작용 없이 우수한 효능을 나타낼 수 있다.The content of the active ingredient is not particularly limited, but may be included as 0.0001 to 10% by weight based on the total weight of the composition. When the active ingredient satisfies the content, it may exhibit excellent efficacy without side effects.
상기 화장료 조성물에는 상기 제조된 산속단 추출물 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다.The cosmetic composition may further include functional additives and components included in the general cosmetic composition in addition to the acid flux extract prepared above. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
본 발명의 화장료 조성물에는 또한, 상기 기능성 첨가물과 더불어 필요에 따라 일반적인 화장료 조성물에 포함되는 성분을 배합해도 된다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In addition to the said functional additive, you may mix | blend the component contained in a general cosmetic composition with the cosmetic composition of this invention as needed. In addition to the other components included, oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation And accelerators, cooling agents, limiting agents, purified water, and the like.
더욱이, 본 발명은 상기 피부 미백용 조성물을 포함하는 피부 외용제에 관한 것으로, 상기 피부 외용제는 피부 외부에서 도포되는 어떠한 것이라도 포함될 수 있는 총칭이며, 다양한 제형의 화장품, 의약품이 여기에 포함될 수 있다. 상기 피부 외용제는 또한, 특별히 제한되지 않으나, 예를 들어 피부 노화 방지용 또는 피부 주름 개선용 피부 외용제일 수 있다.Furthermore, the present invention relates to an external preparation for skin comprising the composition for skin whitening, and the external preparation for skin is a generic term that may include anything applied outside of the skin, and cosmetics and medicines of various formulations may be included therein. The external preparation for the skin is also not particularly limited, but may be, for example, an external preparation for preventing skin aging or improving skin wrinkles.
본 발명은 천연 원료인 산속단 추출물을 함유하는 조성물을 사용하여 우수한 피부 미백 효과를 발견하였다. 본 발명에 의한 피부 미백용 조성물은 후술할 시험예에서 확인할 수 있는 바와 같이, 티로시나제 활성 억제 및 멜라닌 생성 억제 기능을 가져 피부 미백을 증진시킬 수 있다. The present invention has found an excellent skin whitening effect using a composition containing an acid extract, which is a natural raw material. The composition for skin whitening according to the present invention can enhance skin whitening by having a function of inhibiting tyrosinase activity and inhibiting melanin production, as can be seen in the test examples described later.
이하의 실시를 통하여 본 발명이 더욱 상세하게 설명된다. 단, 실시예는 본 발명을 예시하기 위한 것으로서 이들만으로 본 발명의 범위가 한정되는 것은 아니다. The present invention is described in more detail through the following implementation. However, the examples are provided to illustrate the present invention, and the scope of the present invention is not limited only to these examples.
[실시예 1] 산속단 추출물의 제조Example 1 Preparation of Acid Short Extract
산속단의 뿌리를 정제수로 세척하고 건조시킨 다음 세말화하였다. 세말화한 산속단 뿌리 분말 200g을 70% 에탄올 수용액 1리터에 넣고 냉각 콘덴서가 달린 추출기에서 12시간 끓여서 추출한 후 300 메쉬 여과포로 여과하였다. 상기 여과액을 4-15℃에서 7일간 방치하여 숙성시킨 후 와트만 2번 여과지로 여과하였다. 그 후, 상기 추출액을 3리터들이 분액 깔때기에 넣고 여기에 에틸아세테이트 1리터를 가한 후 흔들어서 잘 섞어준 다음 두 층으로 완전히 분리한 후 상층(에틸아세테이트 층)을 취하였다. 하층(물층)을 다시 분액 깔때기로 두 번 더 추출하였다. 분리된 상층을 모두 합한 뒤 냉각 콘덴서가 달린 증류 장치를 이용하여 50℃로 감압 농축하고, 건조하여 건조중량 25.5g의 산속단 추출물을 얻었다.The roots of the acid groups were washed with purified water, dried and then semalized. 200 g of the granulated acidified root powder was placed in 1 liter of an aqueous 70% ethanol solution, extracted by boiling in an extractor equipped with a cooling condenser for 12 hours, and filtered through a 300 mesh filter cloth. The filtrate was left to mature at 4-15 ° C. for 7 days and then filtered through Whatman No. 2 filter paper. Thereafter, the extract was added to a 3-liter separatory funnel, and 1 liter of ethyl acetate was added thereto, shaken well, the mixture was thoroughly separated, and the upper layer (ethyl acetate layer) was taken. The lower layer (water layer) was again extracted twice with a separatory funnel. The combined upper layers were combined, concentrated under reduced pressure at 50 ° C. using a distillation apparatus equipped with a cooling condenser, and dried to obtain an acidic extract having a dry weight of 25.5 g.
[시험예 1] 티로시나제 활성 억제 효과Test Example 1 Inhibitory Effect of Tyrosinase Activity
상기 실시예 1의 산속단 추출물의 티로시나제 활성 억제 효과 측정 시험을 실시하였다. 티로시나제의 활성 측정은 Pomerantz와 Oikawa et al.의 방법으로 시행하였다. 먼저, Mel-ab 세포 2×104 세포를 6웰 배양접시에 시주하고, 상기 실시예 1에서 얻어진 산속단 추출물 10, 50, 100ppm을 처리하고 24시간 배양하였다. 또한, 비교예로서 종래에 미백제 성분으로 알려져 있는 코지산 300ppm에 대해서도 같은 방법으로 배양하였다. 24시간 후, 2 Ci[3H]티로신/㎖의 [3H]L-티로신을 처리하고 24시간 더 배양하였다. 그 후, 세포 배양액을 얻어 3H2O 의 양을 정량하여 그 결과를 하기 표 1에 나타내었다.The tyrosinase activity inhibitory effect measurement test of the acid step extract of Example 1 was carried out. Tyrosinase activity was measured by Pomerantz and Oikawa et al. First, Mel-ab cells 2 × 10 4 cells were placed in a 6-well culture dish, and treated with 10, 50, and 100 ppm of the acid flux extract obtained in Example 1, and cultured for 24 hours. In addition, as a comparative example, 300 ppm of koji acid conventionally known as a whitening agent component was cultured by the same method. After 24 hours, 2 Ci [ 3 H] tyrosine / ml of [ 3 H] L-tyrosine was treated and incubated for another 24 hours. Thereafter, a cell culture was obtained to quantify the amount of 3 H 2 O, and the results are shown in Table 1 below.
표 1 티로시나제 활성 억제 효과
농도(ppm) 티로시나제 활성도(%)
0(대조군) 100
300(비교예,코지산 ) 85
10(실시예 1) 84
50(실시예 1) 68
100(실시예 1) 60
Table 1 Tyrosinase activity inhibitory effect
Concentration (ppm) Tyrosinase Activity (%)
0 (control) 100
300 (Comparative Example, Mt. Koji) 85
10 (Example 1) 84
50 (Example 1) 68
100 (Example 1) 60
상기 표 1에서 보는 바와 같이 산속단 추출물은 비교예에 비하여 티로시나제 활성도가 낮고, 산속단 추출물의 농도가 높아질수록 티로시나제 활성도가 감소하는 것을 알 수 있는바, 산속단 추출물이 티로시나제 활성 억제 효과를 가짐을 확인할 수 있었다. As shown in Table 1, the acid flux extract has a lower tyrosinase activity than the comparative example, and as the concentration of the acid flux extract increases, the tyrosinase activity decreases, and the acid flux extract has an inhibitory effect on tyrosinase activity. I could confirm it.
[시험예 2] 멜라닌 생성 억제 효과[Test Example 2] melanin production inhibitory effect
상기 실시예 1의 산속단 추출물의 멜라닌 생성 억제 효과 측정 시험을 실시하였다. 상기 실시예 1에서 얻어진 산속단 추출물의 세포 내 멜라닌 생성 정도는 Dooley의 방법에 의해 측정하였다. 또한, 비교예로서 종래에 미백제 성분으로 알려져 있는 코지산에 대해서도 측정하였다. 세포주는 C57BL/6의 피부 색소세포에서 유래된 Mel-Ab 세포주를 사용하였다. 배양은 10% 소태반 혈청, 100nM 12-O-테트라데카노일 포볼(Tetradecanoyl Phobol)-13-아세테이트(Acetate), 1nM 콜레라 톡신(Cholera Toxin)을 함유한 DMEM 배지상의 37℃, 5% CO2의 조건하에서 이루어졌다. 배양된 Mel-Ab 세포를 0.25% 트립신(Trypsin)-EDTA로 떼어내고, 24-배양용기(well plate)에 다시 동일한 숫자(1×105cells/well)로 부착시킨 후, 이틀째부터 3일 동안 계속하여 상기 실시예 1의 추출물과 코지산을 10ppm씩 포함한 배지로 교체하였다. 5일째 이후 1N NaOH를 처리함으로써 세포에 포함된 멜라닌을 녹여내고, 400㎚에서의 흡광도 측정을 통해 멜라닌의 양을 측정하였으며, 그 결과를 하기 표 2에 나타내었다. Melanin production inhibitory effect measurement test of the acid step extract of Example 1 was carried out. The degree of melanin production in the acid-producing extract of Example 1 was measured by Dooley's method. In addition, as a comparative example, kojic acid conventionally known as a whitening agent component was measured. The cell line was a Mel-Ab cell line derived from C57BL / 6 skin pigment cells. The culture was performed at 37 ° C., 5% CO 2 in DMEM medium containing 10% fetal placental serum, 100 nM 12-O-tetradecanoyl Phobol-13-acetate, 1 nM Cholera Toxin. Under conditions. Cultured Mel-Ab cells were detached with 0.25% Trypsin-EDTA, attached to the 24-well plate again with the same number (1 × 10 5 cells / well), and then for 2 days to 3 days. Subsequently, the extract and kojic acid of Example 1 were replaced with a medium containing 10 ppm each. After 5 days, the melanin contained in the cells was dissolved by treating with 1N NaOH, and the amount of melanin was measured by measuring absorbance at 400 nm. The results are shown in Table 2 below.
표 2 멜라닌 생성 억제 효과
물질 멜라닌의 생성량(%)
대조군 100
비교예 75.5
실시예 1 55.6
TABLE 2 Melanin production inhibitory effect
matter Production amount of melanin (%)
Control 100
Comparative example 75.5
Example 1 55.6
상기 표 2에서 보는 바와 같이 산속단 추출물의 멜라닌의 생성량이 비교예에 비하여 감소하였고, 이로써 산속단 추출물이 멜라닌 생성을 억제시키는 효과를 가짐을 알 수 있었다.As shown in Table 2, the production amount of melanin of the acid-fast extract was reduced compared to the comparative example, and thus it was found that the acid-fast extract has an effect of inhibiting melanin production.
본 발명의 산속단 추출물을 함유하는 조성물의 제형예를 하기에서 설명하지만, 본 발명의 조성물이 이 예로만 한정되는 것은 아니다. Although the formulation example of the composition containing the acid-fast extract of this invention is demonstrated below, the composition of this invention is not limited only to this example.
[제형예 1] 로션형 제형Formulation Example 1 Lotion Formulation
실시예 1의 산속단 추출물 3.00Acid step extract of Example 1 3.00
L-아스코르빈산-2-인산마그네슘염 1.00L-ascorbic acid-2-magnesium phosphate salt 1.00
수용성 콜라겐 (1% 수용액) 1.00Water Soluble Collagen (1% Aqueous Solution) 1.00
시트르산나트륨 0.10Sodium Citrate 0.10
시트르산 0.05Citric Acid 0.05
감초 엑기스 0.20Licorice Extract 0.20
1,3-부틸렌글리콜 3.001,3-butylene glycol 3.00
정제수 잔량Purified water level
(단위: 중량%)(Unit: weight%)
[제형예 2] 크림형 제제Formulation Example 2 Cream-Type Formulation
실시예 1의 산속단 추출물 1.00Acid step extract of Example 1 1.00
폴리에틸렌글리콜모노스테아레이트 2.00Polyethylene Glycol Monostearate 2.00
자기유화형 모노스테아르산글리세린 5.00Self-emulsifying glycerin monostearate 5.00
세틸알코올 4.00Cetyl Alcohol 4.00
스쿠알렌 6.00Squalene 6.00
트리2-에틸헥산글리세릴 6.00Tri2-ethylhexaneglyceryl 6.00
스핑고당지질 1.00Sphingolipids 1.00
1,3-부틸렌글리콜 7.001,3-butylene glycol 7.00
정제수 잔량Purified water level
(단위: 중량%)(Unit: weight%)
[제형예 3] 팩형 제제Formulation Example 3 Packed Formulations
실시예 1의 산속단 추출물 5.00Acid Step Extract of Example 1 5.00
폴리비닐알코올 13.00Polyvinyl Alcohol 13.00
L-아스코르빈산-2-인산마그네슘염 1.00L-ascorbic acid-2-magnesium phosphate salt 1.00
라우로일히드록시프롤린 1.00Lauroylhydroxyproline 1.00
수용성 콜라겐 (1% 수용액) 2.00Water Soluble Collagen (1% Aqueous Solution) 2.00
1,3-부틸렌글리콜 3.001,3-butylene glycol 3.00
에탄올 5.00Ethanol 5.00
정제수 잔량Purified water level
(단위: 중량%)(Unit: weight%)
[제형예 4] 미용액형 제제Formulation Example 4 Cosmetic Liquid Formulation
실시예 1의 산속단 추출물 2.00Acid step extract of Example 1 2.00
히드록시에틸렌셀룰로오스 (2% 수용액) 12.00Hydroxyethylene Cellulose (2% Aqueous Solution) 12.00
크산탄검 (2% 수용액) 2.00Xanthan gum (2% aqueous solution) 2.00
1,3-부틸렌글리콜 6.001,3-butylene glycol 6.00
진한 글리세린 4.00Dark Glycerin 4.00
히알루론산나트륨 (1% 수용액) 5.00Sodium Hyaluronate (1% aqueous solution) 5.00
정제수 잔량Purified water level
(단위: 중량%)(Unit: weight%)

Claims (6)

  1. 산속단 추출물을 유효성분으로 함유하는 피부 미백용 조성물. Skin whitening composition containing an acid extract as an active ingredient.
  2. 제 1항에 있어서,The method of claim 1,
    상기 산속단 추출물은 탄소수 1 내지 4의 무수 및 함수 저급 알코올, 아세톤, 부틸렌글리콜, 에틸아세테이트, 디에틸아세테이트, 디에틸에테르, 벤젠, 클로로포름 및 헥산으로 이루어진 군에서 선택된 어느 하나 이상의 용매를 사용하여 추출된 것인 피부 미백용 조성물. The acid-fast extract may be any one or more solvents selected from the group consisting of anhydrous and hydrous lower alcohols having 1 to 4 carbon atoms, acetone, butylene glycol, ethyl acetate, diethyl acetate, diethyl ether, benzene, chloroform and hexane The composition for skin whitening is extracted.
  3. 제 1항에 있어서, The method of claim 1,
    상기 산속단 추출물은, 탄소수 1 내지 4의 무수 및 함수 저급 알코올, 아세톤 및 부틸렌글리콜을 포함하는 극성 용매 중 어느 하나 이상을 사용한 1차 추출 및 에틸아세테이트, 디에틸아세테이트, 디에틸에테르, 벤젠, 클로로포름 및 헥산을 포함하는 저극성 용매 중 어느 하나 이상을 사용한 2차 추출을 통하여 추출된 것인 피부 미백용 조성물. The acid-fast extract, the primary extraction using any one or more of a polar solvent containing anhydrous and hydrous lower alcohols having 1 to 4 carbon atoms, acetone and butylene glycol, and ethyl acetate, diethyl acetate, diethyl ether, benzene, The composition for skin whitening is extracted through the secondary extraction using any one or more of a low polar solvent containing chloroform and hexane.
  4. 제 1항에 있어서, The method of claim 1,
    상기 산속단 추출물의 함량은 조성물 총 중량에 대하여 0.0001 내지 10중량%인 피부 미백용 조성물.The content of the acid flux extract is a composition for skin whitening is 0.0001 to 10% by weight based on the total weight of the composition.
  5. 제 1항에 있어서, The method of claim 1,
    상기 피부 미백용 조성물은 멜라닌 생성 억제를 통해 피부를 미백시키는 것을 특징으로 하는 피부 미백용 조성물.The skin whitening composition is a skin whitening composition, characterized in that for whitening the skin through the inhibition of melanin production.
  6. 제 1항에 있어서, The method of claim 1,
    상기 피부 미백용 조성물은 티로시나제 활성 억제를 통해 피부를 미백시키는 것을 특징으로 하는 피부 미백용 조성물.The skin whitening composition is a skin whitening composition, characterized in that the skin whitening through inhibiting tyrosinase activity.
PCT/KR2011/008693 2010-11-19 2011-11-15 Composition for whitening skin containing phlomis koraiensis nakai extract as active ingredient WO2012067398A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100115394A KR101832862B1 (en) 2010-11-19 2010-11-19 Compositions containing an extract of phlomis korainensis nakai for skin whitening
KR10-2010-0115394 2010-11-19

Publications (2)

Publication Number Publication Date
WO2012067398A2 true WO2012067398A2 (en) 2012-05-24
WO2012067398A3 WO2012067398A3 (en) 2012-07-12

Family

ID=46084496

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008693 WO2012067398A2 (en) 2010-11-19 2011-11-15 Composition for whitening skin containing phlomis koraiensis nakai extract as active ingredient

Country Status (2)

Country Link
KR (1) KR101832862B1 (en)
WO (1) WO2012067398A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102233370B1 (en) * 2020-09-16 2021-03-30 주식회사 다나제약 Method of manufacture of kennel extract, kennel solvent extract manufactured by the above method, and method of manufacture of natural mineral ion water using the kennel solvent extract

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090130584A (en) * 2008-06-16 2009-12-24 (주)코바스 Cosmetic composition comprising an extract of mixed herbs having skin whitening and wrinkle improving activity
KR20100028602A (en) * 2010-01-25 2010-03-12 (주)내츄럴엔도텍 Compositions for improving skin conditions comprising extract of phlomis umbrosa
KR20100046528A (en) * 2008-10-27 2010-05-07 한국식품연구원 Composition for anti-oxidative and anti-inflammatory activity comprising the extract and fraction of phlomis radix
KR20100106181A (en) * 2009-03-23 2010-10-01 (주)내츄럴엔도텍 Compositions for preventing or treating insomnia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090130584A (en) * 2008-06-16 2009-12-24 (주)코바스 Cosmetic composition comprising an extract of mixed herbs having skin whitening and wrinkle improving activity
KR20100046528A (en) * 2008-10-27 2010-05-07 한국식품연구원 Composition for anti-oxidative and anti-inflammatory activity comprising the extract and fraction of phlomis radix
KR20100106181A (en) * 2009-03-23 2010-10-01 (주)내츄럴엔도텍 Compositions for preventing or treating insomnia
KR20100028602A (en) * 2010-01-25 2010-03-12 (주)내츄럴엔도텍 Compositions for improving skin conditions comprising extract of phlomis umbrosa

Also Published As

Publication number Publication date
KR101832862B1 (en) 2018-03-02
WO2012067398A3 (en) 2012-07-12
KR20120054150A (en) 2012-05-30

Similar Documents

Publication Publication Date Title
WO2020060060A1 (en) Cosmetic composition comprising centella asiatica adventitious root extract as effective ingredient for skin whitening and wrinkle reduction
WO2007098873A1 (en) Combination or plant extract comprising verbascoside and luteolin and their use in a cosmetically or pharmaceutical composition for pigmentation modulation
KR101600957B1 (en) Whitening composition for external skin application containing Oldenlandia diffusa willd Rheum undulatum and Broussonetia kazinoki extract
WO2012067404A2 (en) Composition for anti-aging containing artemisia annua l. as active ingredient
WO2012002782A2 (en) Skin-whitening composition for external application on skin containing extracts from paper mulberry flowers and fruits
WO2018174453A1 (en) Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis
WO2020246766A1 (en) Composition for preventing or alleviating skin aging, containing rhodiola sachalinensis extract fermented with bovista plumbea
KR100850686B1 (en) Extract of nigella glandulifera freyn et sint having whitening activity and the cosmetic composition comprising thereof
KR100742267B1 (en) Extract of Chrysanthemum morifolium Ramat, the preparation method thereof and the cosmetic composition comprising the same for whitening
WO2012173382A2 (en) Skin composition for external use containing tanshinone ii a as active ingredient
KR101823909B1 (en) Functional Cosmetic Composition Comprising Vitamin C Derivatives
WO2018021802A1 (en) Composition for inhibiting sebum secretion comprising peach sprout extract
KR101854766B1 (en) Skin whitening complex containing trihydroxyisoflavone and glycyrrhiza uralensis extracts
WO2012067398A2 (en) Composition for whitening skin containing phlomis koraiensis nakai extract as active ingredient
KR100829718B1 (en) Cosmetic Composition for Whitening the Skin Comprising the Extract of Ilex rotunda as Active Ingredient
KR100466379B1 (en) Composition for skin whitening
KR101317433B1 (en) The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage
WO2024010355A1 (en) Anti-aging composition containing extract from gosori wine lees
KR102435602B1 (en) Cosmetic composition for skin improvement containing aloe vera adventitious root extract
WO2018052152A1 (en) Antiaging composition for external preparation for skin, containing extract of germinated glycine gracilis as active ingredient
WO2013147350A1 (en) Cosmetic composition using apios americana medikus, and preparation method thereof
WO2016024756A1 (en) Cosmetic composition for skin whitening
WO2023058993A1 (en) Composition for anti-aging and skin improvement, comprising complex of indian gooseberry extract and barley sprout extract (ib complex) as active ingredient
WO2010013885A1 (en) Cosmetic composition containing salt-fermented extract of natural materials
WO2010058984A2 (en) Antioxidant composition containing extract of processed chrysanthemum indicum or citrus unshiu peel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11841484

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/09/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11841484

Country of ref document: EP

Kind code of ref document: A2